AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7714229
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of oral SDZ ENS-163 with intravenous scopolamine
Trial: 7714229
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo with intravenous saline
Trial: 30476258
Drug: Clinic-community treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-community treatment program (Bull City Fit)
Trial: 30476258
Drug: Clinic-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinic-only treatment program
Trial: 1012648
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment programs
Trial: 12953725
Drug: Sufentanil 1
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1 microg/ml in normal saline (Group S)
Trial: 12953725
Drug: Sufentanil 1
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1 microg/ml with bupivacaine 0.125% (Group SB)
Trial: 7677723
Drug: Imagery rehearsal
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imagery rehearsal treatment
Trial: 2288408
Drug: Tramadol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (0.5 mg/kg)
Trial: 7015174
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of kanamycin 500 mg plus clindamycin 600 mg intramuscularly
Trial: 30992395
Drug: WEB implant
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: WEB implant
Trial: 21226941
Drug: Multifamily group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifamily group psychoeducation (MFG) with concurrent cognitive remediation
Trial: 8836264
Drug: Ketoprofen 300
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 300 mg (bolus followed by continuous infusion)
Trial: 1417380
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine (0.1 mg/24 h for 4 days, then 0.2 mg/24 h for 3 days, continued for 6 weeks after target quit day)
Trial: 2666565
Drug: Transdermal clonidine
RxNorm normalized name: clonidine Transdermal System
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal clonidine
Trial: 6719387
Drug: Dipyridamole (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (375 mg/d)
Trial: 6719387
Drug: RA 233
RxNorm normalized name: RAS
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RA 233 (1500 mg/d)
Trial: 27085624
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Epirubicin (EPI) and Interferon-α2a (IFN)
Trial: 20720535
Drug: Oxytocin (OXT)
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin (OXT) 24 IU or 40.32 μg
Trial: 16158782
Drug: Nasal budesonide
RxNorm normalized name: budesonide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal budesonide plus oral zafirlukast twice a day
Trial: 16158782
Drug: Nasal budesonide
RxNorm normalized name: budesonide Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal budesonide plus oral loratadine/pseudoephedrine twice a day
Trial: 12043956
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg (Avandia tablets, 4 mg x 2)
Trial: 12043956
Drug: Rosiglitazone 8
RxNorm normalized name: rosiglitazone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 8 mg after pretreatment with sucralfate 2 g (Recolfate tablets, 1 g x 2)
Trial: 8162670
Drug: Disulfiram (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (500 mg orally)
Trial: 31016613
Drug: Leflunomide 10
RxNorm normalized name: leflunomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide 10 mg
Trial: 7488280
Drug: Leflunomide 25
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide 25 mg
Trial: 7488280
Drug: Leflunomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leflunomide (10 mg and 25 mg)
Trial: 2148849
Drug: Ridogrel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridogrel (2 x 300 mg per day for 2 1/2 days)
Trial: 2148849
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 x 300 mg per day for 2 1/2 days)
Trial: 7016067
Drug: Cimetidine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (various doses)
Trial: 7016067
Drug: Cimetidine (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (2,400 mg/day)
Trial: 25855055
Drug: Oral consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral consumption of Respecta(®) complex (L. acidophilus La‐14, L. rhamnosus HN001, and bovine lactoferrin) twice daily for 2 weeks
Trial: 25855055
Drug: Oral consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral consumption of Respecta(®) complex
Trial: 22473713
Drug: Vaniprevir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaniprevir (300 mg BID, 600 mg BID, 600 mg QD, or 800 mg QD)
Trial: 17329659
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vaccine Day and educational campaign
Trial: 17329659
Drug: Vaccine Day
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine Day alone
Trial: 15334330
Drug: Naloxone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (8 mg, four times daily via gastric tube)
Trial: 3384588
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of pyridoxine-HCl daily supplementation for one year
Trial: 27550387
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) as add-on therapy
Trial: 14687872
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (150 mg/day)
Trial: 9177952
Drug: Moclobemide 600
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 600 mg per day
Trial: 9177952
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg per day
Trial: 8479230
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg three times per day for the first month, then 100 mg three times per day for the next two months
Trial: 2870610
Drug: 2% nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% nitroglycerin gel adhesive administered transdermally by an adhesive (Topinitro), 2.5‐10 mg/day, individually titrated for 28 days
Trial: 2843039
Drug: Enhanced-potency inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced-potency inactivated polio vaccines
Trial: 14506371
Drug: Inactivated polio
RxNorm normalized name: Inactivated polio vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated polio vaccine
Trial: 31050931
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) treatment
Trial: 31373272
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (Space from Depression), delivered over 8 weeks, 7 modules.
Trial: 28661316
Drug: 50 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g/d soya protein
Trial: 28661316
Drug: 25 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/d soya protein
Trial: 28661316
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g/d soya protein)
Trial: 23839277
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (10 µg) with 2.6 ml of 0.5% hyperbaric bupivacaine (13 mg)
Trial: 23839277
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 2.8 ml of 0.5% hyperbaric bupivacaine (14 mg)
Trial: 21703206
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg/day from week 20 to 32 of gestation (n=135)
Trial: 19345439
Drug: Telbivudine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine treatment
Trial: 19307526
Drug: Metformin hydrochloride,
RxNorm normalized name: MetFORMIN Hydrochloride, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin hydrochloride, 850 mg, added to insulin therapy (1-3 times daily)
Trial: 2246698
Drug: Exosurf (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosurf (5 ml/kg dose)
Trial: 27552585
Drug: High-dose intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intranasal oxytocin (32 IU per day)
Trial: 27552585
Drug: Low-dose intranasal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intranasal oxytocin (16 IU per day)
Trial: 25712685
Drug: Rilotumumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (15 mg/kg) plus epirubicin, cisplatin, and capecitabine (ECX)
Trial: 25712685
Drug: Rilotumumab (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilotumumab (7.5 mg/kg) plus ECX
Trial: 11078982
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement (2 IU GH/m daily for 4 months)
Trial: 8862480
Drug: Vitamins (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamins (vitamin E, 15 mg and vitamin C, 120 mg) and beta-carotene, 6 mg
Trial: 8862480
Drug: Trace elements
RxNorm normalized name: trace elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trace elements (zinc, 20 mg, selenium, 100 micrograms)
Trial: 1799477
Drug: Interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alfa-2b in a dose of 5 million units (MU) three times per week
Trial: 27647873
Drug: Eluxadoline 300
RxNorm normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eluxadoline 300 mg
Trial: 27647873
Drug: Eluxadoline 100
RxNorm normalized name: eluxadoline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eluxadoline 100 mg (intranasal)
Trial: 27647873
Drug: Eluxadoline 200
RxNorm normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eluxadoline 200 mg (intranasal)
Trial: 27647873
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral study)
Trial: 27647873
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal study)
Trial: 20230454
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg amitriptyline
Trial: 18383000
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg paroxetine
Trial: 20550020
Drug: Pramipexole 0.25
RxNorm normalized name: pramipexole 0.25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole 0.25 mg
Trial: 12682318
Drug: L-dopa therapy
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa therapy
Trial: 12682318
Drug: L-dopa-naive (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa-naive (control group)
Trial: 9441116
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment in IPF patients
Trial: 6391270
Drug: Innovar (fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Innovar (fentanyl and droperidol, 2.5-5 ml)
Trial: 22653705
Drug: Atopaxar (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atopaxar (50, 100, or 200 mg daily)
Trial: 18562985
Drug: Diaphragm with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm with placebo gel (HEC)
Trial: 15653582
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (balloon angioplasty alone or stenting)
Trial: 15653582
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment with severe stenosis
Trial: 12419136
Drug: 25% metronidazol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% metronidazol gel
Trial: 28008557
Drug: Conventional decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional decongestive therapy
Trial: 25044235
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of insulin 0.1U • kg‐1 • h‐1
Trial: 1728908
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction and placebo drug treatment
Trial: 3768929
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg of chlorthalidone
Trial: 2831525
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of atenolol
Trial: 31660991
Drug: Caffeine 300
RxNorm normalized name: caffeine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 300 mg (CAFF300)
Trial: 31660991
Drug: TeaCrine® 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TeaCrine® 300 mg (TEA300)
Trial: 31660991
Drug: TeaCrine® +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TeaCrine® + Caffeine (COMBO; 150 mg/150 mg)
Trial: 31660991
Drug: Placebo 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 300 mg (PLA)
Trial: 23031354
Drug: Low glucose
RxNorm normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glucose (LG; 2.5 mg/kg per minute)
Trial: 11981396
Drug: Nimodipine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (30 mg oral tablet taken three times per day)
Trial: 11981396
Drug: Cinnarizine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine (150 mg oral capsule taken once daily with dinner)
Trial: 7255508
Drug: Meptazinol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol (1 mg/kg)
Trial: 31845894
Drug: Ticagrelor monotherapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor monotherapy (23-month duration after one month of DAPT)
Trial: 31845894
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment (12-month DAPT followed by 12 months of aspirin)
Trial: 27106272
Drug: Reference treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference treatment
Trial: 31150789
Drug: Sesame Oral
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame Oral Immunotherapy (OIT)
Trial: 22848592
Drug: Standard pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pain therapy procedures
Trial: 20354543
Drug: Dose-dense administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-dense administration of paclitaxel
Trial: 20354543
Drug: Intraperitoneal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal administration of platinum and paclitaxel
Trial: 20354543
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of pegylated liposomal doxorubicin combined with carboplatin
Trial: 16169422
Drug: Enoxaparin 80
RxNorm normalized name: ENOXAPARIN 80MG/0.8ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 80 mg/day
Trial: 12471862
Drug: Arthritis treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthritis treatment
Trial: 12471862
Drug: Diabetes treatment
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes treatment
Trial: 19809365
Drug: Hypertension treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertension treatment
Trial: 9472846
Drug: Fluoxetine (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (5-10 mg/day)
Trial: 7611312
Drug: Topical medication
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medication first
Trial: 2203250
Drug: High-fat evening
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High-fat evening meal (41 g fat)
Trial: 19067285
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (iNO) at 5 to 10 ppm
Trial: 9476183
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg/lansoprazole 15 mg
Trial: 9476183
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg/placebo
Trial: 9476183
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg/ranitidine 150 mg
Trial: 9476183
Drug: ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine 300 mg/placebo
Trial: 9476183
Drug: lansoprazole (half
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole (half dose formulation)
Trial: 3680603
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 1 mg alprazolam
Trial: 3680603
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 1 mg alprazolam
Trial: 26771737
Drug: Citalopram (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (30 mg/day, titrated over 3 weeks)
Trial: 24410954
Drug: n-3 FA
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 FA supplement (2.3 g daily for 6 months)
Trial: 16086704
Drug: 7-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Trial: 16086704
Drug: 10-day rabeprazole-based
RxNorm normalized name: rabeprazole sodium 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day rabeprazole-based triple therapy (rabeprazole 20 mg, clarithromycin 500 mg, amoxicillin 1 g, all twice a day)
Trial: 15786549
Drug: 7-day rabeprazole-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day rabeprazole-based triple therapy
Trial: 16086704
Drug: 10-day rabeprazole-based
RxNorm normalized name: rabeprazole sodium 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day rabeprazole-based triple therapy
Trial: 6116728
Drug: Hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + cimetidine (300 mg q.i.d.)
Trial: 6116728
Drug: Hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + placebo
Trial: 6116728
Drug: Hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + terbutaline (2.5 mg q.i.d.)
Trial: 6116728
Drug: Hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + cyproheptadine (4 mg q.i.d.)
Trial: 6116728
Drug: Hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyzine pamoate (25 mg q.i.d.) + chlorpheniramine (4 mg q.i.d.)
Trial: 24941138
Drug: Black cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black cohosh extract 40 mg/day
Trial: 23328330
Drug: Amitriptyline (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (25 to 50 mg/d)
Trial: 23328330
Drug: Divalproate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproate (500 to 750 mg/d)